STRIDE open-label extension
57 evidence topics · 10 sources
Objective
Purpose of the open-label extension in the ClinicalTrials.gov record
Location and study date
Study start, completion, and record dates in the ClinicalTrials.gov record
“Study Start (Actual) 2023-01-17” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2027-12-01” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-12-31” (opens the source at this quote in a new tab)
“First Posted 2023-02-22” (opens the source at this quote in a new tab)
Completion dates estimated at registration, February 2023, superseded in July 2026
Recruitment status and last update in the ClinicalTrials.gov record
Countries of trial sites in the ClinicalTrials.gov record
| Country | A site listed for the country in the record |
|---|---|
| United States | “Rogers, Arkansas, United States, 72758” |
| Canada | “Surrey, British Columbia, Canada, V3V 0C6” |
North American sites and date of first entry into the open-label extension
Study design
Design in the ClinicalTrials.gov record
Ongoing phase 2 extension with enrollment within 28 days of the STRIDE end-of-study visit
Protocol amendment of January 2024 moving all participants to 40 mg twice daily
Visit and pharmacokinetic sampling schedule
Rollover after the STRIDE week 16 visit and timing of the switch to twice-daily dosing
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
Eligibility criteria and prohibited treatments in the supplementary material
Treatment
Allocation to 40 mg once or twice daily by STRIDE dose arm
Numbers allocated to each extension arm from each STRIDE arm
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using treatment-emergent and serious adverse events as the primary endpoint
Primary and secondary outcomes in the ClinicalTrials.gov record
Regulatory guidance on one-year exposure in the safety database
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Enrollment estimated at registration, February 2023, superseded in May 2024
Sample size based on STRIDE completers without a power calculation
Description of analysis sets
Composition of the 40 mg once-daily and overall 40 mg twice-daily groups in the safety and efficacy tables
Analysis sets by arm, ITT population
| Analysis set | Original 40 mg QD (N = 82) | Original 40 mg BID (N = 83) | 40 mg QD to 40 mg BID (N = 65) | Overall 40 mg BID (N = 148) | Overall (N = 165) |
|---|---|---|---|---|---|
| ITT population | “82” | “83” | “65” | “148” | “165” |
| mITT population | “82 (100.0)” | “82 (98.8)” | “65 (100.0)” | “147 (99.3)” | “164 (99.4)” |
| Safety analysis set | “82 (100.0)” | “82 (98.8)” | “65 (100.0)” | “147 (99.3)” | “164 (99.4)” |
| PK analysis set | “82 (100.0)” | “82 (98.8)” | “65 (100.0)” | “147 (99.3)” | “164 (99.4)” |
Post-hoc treat-to-target analyses and mixed model for percent change in PASI
Results
Participant disposition
Rollover from STRIDE: randomized, completing, ineligible, and declining participants
“228 Randomized Phase 2 STRIDE Subjects” (opens the source at this quote in a new tab)
“204 Subjects Completing STRIDE” (opens the source at this quote in a new tab)
“30 Ineligible and not participating in OLE” (opens the source at this quote in a new tab)
“25: OLE Not initiated in Czech Republic” (opens the source at this quote in a new tab)
“5: Did not meet OLE inclusion criteria” (opens the source at this quote in a new tab)
“9 Eligible for OLE but chose not to participate” (opens the source at this quote in a new tab)
Enrollment of 165 participants and one participant not dosed
Participants ongoing and discontinuations at the 52-week data cut-off
Disposition by arm, ITT population
| Disposition | Original 40 mg QD (N = 82) | Original 40 mg BID (N = 83) | 40 mg QD to 40 mg BID (N = 65) | Overall 40 mg BID (N = 148) | Overall (N = 165) |
|---|---|---|---|---|---|
| Patients ongoing in study, n (%) | “0 (0)” | “66 (79.5)” | “60 (92.3)” | “126 (85.1)” | “126 (76.4)” |
| Patients who switched to 40 mg BID, n (%) | “65 (79.3)” | “-” | “-” | “-” | “65 (39.4)” |
| Discontinued: withdrawal by subject | “6 (7.3)” | “3 (3.6)” | “4 (6.2)” | “7 (4.7)” | “13 (7.9)” |
| Discontinued: lost to follow-up | “3 (3.7)” | “6 (7.2)” | “1 (1.5)” | “7 (4.7)” | “10 (6.1)” |
| Discontinued: inadequate response | “6 (7.3)” | “1 (1.2)” | “0 (0)” | “1 (0.7)” | “7 (4.2)” |
| Discontinued: adverse event | “1 (1.2)” | “4 (4.8)” | “0 (0)” | “4 (2.7)” | “5 (3.0)” |
| Discontinued: pregnancy | “1 (1.2)” | “0 (0)” | “0 (0)” | “0 (0)” | “1 (0.6)” |
| Discontinued: protocol deviation | “0 (0)” | “1 (1.2)” | “0 (0)” | “1 (0.7)” | “1 (0.6)” |
| Discontinued: death | “0 (0)” | “0 (0)” | “0 (0)” | “0 (0)” | “0 (0)” |
Basis of the disposition counts, data date, and the participant not dosed
Baseline characteristics
Demographics and prior treatment, ITT population
Demographic and baseline characteristics by original dose assignment, ITT population
Efficacy results
Week 52 response rates stated for 40 mg twice daily in the abstract and text, mITT population
Week 28 and week 52 skin responses by original and overall 40 mg twice-daily groups, mITT population, mNRI
| Endpoint | Week 28, original 40 mg QD (N = 80) | Week 52, original 40 mg BID (N = 80) | Week 52, overall 40 mg BID (N = 144) |
|---|---|---|---|
| PASI-75, n (%) | “54 (67.5)” | “62 (77.5)” | “112 (77.8)” |
| PASI-75, 95% CI | “56.1, 77.6” | “66.8, 86.1” | “70.1, 84.3” |
| PASI-90, n (%) | “36 (45.0)” | “49 (61.3)” | “90 (62.5)” |
| PASI-90, 95% CI | “33.8, 56.5” | “49.7, 71.9” | “54.1, 70.4” |
| PASI-100, n (%) | “15 (18.8)” | “31 (38.8)” | “47 (32.6)” |
| PASI-100, 95% CI | “10.9, 29.0” | “28.1, 50.3” | “25.1, 40.9” |
| sPGA-0/1, n (%) | “41 (51.3)” | “49 (61.3)” | “86 (59.7)” |
| sPGA-0/1, 95% CI | “39.8, 62.6” | “49.7, 71.9” | “51.2, 67.8” |
| sPGA-0, n (%) | “15 (18.8)” | “31 (38.8)” | “47 (32.6)” |
| sPGA-0, 95% CI | “10.9, 29.0” | “28.1, 50.3” | “25.1, 40.9” |
Maintenance of STRIDE week 12 PASI-75 response and continued improvement at week 52, 40 mg twice daily
Improvement in PASI response category from STRIDE week 12 to extension week 52, 40 mg twice daily, mITT population
| Responder status at week 12 of STRIDE | N | Improvement to PASI-75, n (%) | Improvement to PASI-90, n (%) | Improvement to PASI-100, n (%) | Any improvement, n (%) |
|---|---|---|---|---|---|
| Below PASI-75 | “38” | “7 (18.4)” | “8 (21.1)” | “12 (31.6)” | “27 (71.1)” |
| PASI-75 and below PASI-90 | “24” | “----” | “4 (16.7)” | “10 (41.7)” | “14 (58.3)” |
| PASI-90 and below PASI-100 | “11” | “----” | “----” | “4 (36.4)” | “4 (36.4)” |
| Total | “73” | “----” | “----” | “----” | “45 (61.6)” |
Discontinuations among week 52 nonresponders in the original 40 mg twice-daily group
Week 52 compared with extension week 12 in the original 40 mg twice-daily group, mNRI, n = 80
Week 28 PASI and sPGA responses with 40 mg twice daily, mNRI, March 2024 data cut
Treat-to-target thresholds at week 52 with 40 mg twice daily, post-hoc analysis
Health-related quality of life and patient-reported outcomes
DLQI and pruritus responses at week 52 stated in the text, 40 mg twice daily
Week 28 and week 52 patient-reported outcomes by original and overall 40 mg twice-daily groups, mITT population, mNRI
| Endpoint | Week 28, original 40 mg QD (N = 80) | Week 52, original 40 mg BID (N = 80) | Week 52, overall 40 mg BID (N = 144) |
|---|---|---|---|
| DLQI 0/1, n (%) | “41 (51.3)” | “49 (61.3)” | “87 (60.4)” |
| DLQI 0/1, 95% CI | “39.8, 62.6” | “49.7, 71.9” | “51.9, 68.5” |
| DLQI 4-point decrease, n (%) | “49 (61.3)” | “55 (68.8)” | “103 (71.5)” |
| DLQI 4-point decrease, 95% CI | “49.7, 71.9” | “57.4, 78.7” | “63.4, 78.7” |
| Average pruritus NRS score below 4, n (%) | “54 (67.5)” | “65 (81.3)” | “115 (79.9)” |
| Average pruritus NRS score below 4, 95% CI | “56.1, 77.6” | “71.0, 89.1” | “72.4, 86.1” |
| Worst pruritus NRS score below 4, n (%) | “51 (63.8)” | “63 (78.8)” | “112 (77.8)” |
| Worst pruritus NRS score below 4, 95% CI | “52.2, 74.2” | “68.2, 87.1” | “70.1, 84.3” |
| Improvement in worst pruritus NRS score of at least 4, post-hoc, n (%) | “44 (55.0)” | “47 (58.8)” | “89 (61.8)” |
| Improvement in worst pruritus NRS score of at least 4, post-hoc, 95% CI | “43.5, 66.2” | “47.2, 69.6” | “53.3, 69.8” |
Itch control and DLQI at week 52 stated in the company release, original 40 mg twice-daily group
Minimal or no impact on quality of life at weeks 12 and 52 with 40 mg twice daily
Safety results
Adverse events with exposure-adjusted incidence rates through week 52, safety analysis population
| Event, n (%) [EAIR] | Original 40 mg QD (N = 82) | Overall 40 mg BID (N = 147) | Overall (N = 164) |
|---|---|---|---|
| Patients with at least 1 TEAE | “50 (61.0) [122.76]” | “73 (49.7) [102.33]” | “108 (65.9) [108.18]” |
| Patients with TEAE leading to study drug discontinuation | “1 (1.2) [1.55]” | “5 (3.4) [4.19]” | “6 (3.7) [3.26]” |
| Patients with TEAE grade 3 or higher | “3 (3.7) [4.66]” | “6 (4.1) [5.12]” | “8 (4.9) [4.42]” |
| Upper respiratory tract infection | “3 (3.7) [4.71]” | “13 (8.8) [11.66]” | “16 (9.8) [9.20]” |
| Nasopharyngitis | “10 (12.2) [16.88]” | “6 (4.1) [5.15]” | “14 (8.5) [8.09]” |
| COVID-19 | “3 (3.7) [4.74]” | “8 (5.4) [6.88]” | “11 (6.7) [6.17]” |
| Headache | “5 (6.1) [8.28]” | “5 (3.4) [4.28]” | “10 (6.1) [5.71]” |
| Patients with at least 1 treatment-emergent SAE | “2 (2.4) [3.10]” | “4 (2.7) [3.39]” | “6 (3.7) [3.29]” |
| Patients with SAEs related to study drug | “2 (2.4) [3.10]” | “2 (1.4) [1.67]” | “4 (2.4) [2.17]” |
| Patients with TEAE leading to death | “0 (0) [-]” | “0 (0) [-]” | “0 (0) [-]” |
Adverse events leading to discontinuation, frequency threshold, and severity of the most frequent events
Overall tolerability, severity, acne, and folliculitis
Comparison of the once-daily and twice-daily arms, including related adverse events
Treatment-related adverse events with exposure-adjusted incidence rates, September 2024 data cut
Laboratory values, lipids, cytopenia, rhabdomyolysis, and tuberculosis
Herpes zoster, electrocardiograms, and thromboembolic events
Study limitations
Summary
- The authors state that this was an open-label study with limited sample size and no placebo or active comparator.
- No formal power calculation was performed; the sample consisted of STRIDE completers who qualified and chose to enroll. The extension was not initiated in the Czech Republic, which made 25 STRIDE completers ineligible, and the study was conducted at North American sites only.
- Dose assignment followed the STRIDE arm for participants from the 10 mg QD and 20 mg QD arms (40 mg QD) and the 20 mg BID and 40 mg BID arms (40 mg BID); participants from the placebo and 40 mg QD arms were allocated to either dose. The ClinicalTrials.gov record lists the allocation as randomized.
- A protocol amendment on 2 January 2024 moved all participants to 40 mg BID between weeks 40 and 64, so the overall 40 mg BID group (N = 148, intent-to-treat) includes 65 participants who switched from 40 mg QD.
- Efficacy baseline was STRIDE Day 1, and participants entered the extension with a mean PASI of 8.5. Responder analyses used modified nonresponder imputation, carrying the last observation forward for discontinuations other than for AEs or inadequate response.
- Week 52 PASI 100 with 40 mg BID is 39% in the article text, 31 of 80 (38.8%) in the original 40 mg BID group, and 47 of 144 (32.6%) in the overall 40 mg BID group. Itch control in the original 40 mg BID group is reported as “NRS≤4, 81.3%” in a press release and as average pruritus NRS below 4 in 65 participants (81.3%) in the article table.
- Data cutoffs differ: the supplement includes data from 18 November 2024, and a congress poster by Blauvelt et al. displays safety data from the 06 SEP 2024 data cut. The treat-to-target analyses and the analysis of an improvement of at least 4 points in worst pruritus NRS are post hoc.
- The study is ongoing; 126 participants (76.4%) were continuing treatment at the 52-week data cut-off, and study completion is estimated for 2027-12-31.